Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has been assigned an average recommendation of “Buy” from the nine analysts that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $20.40.
Several equities analysts recently issued reports on the stock. Seaport Global Securities reiterated a “buy” rating and set a $21.00 price target on shares of Vanda Pharmaceuticals in a research report on Wednesday, February 28th. BidaskClub upgraded shares of Vanda Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, February 21st. Oppenheimer set a $27.00 price target on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, March 5th. Jefferies Group reissued a “buy” rating and set a $20.00 price objective on shares of Vanda Pharmaceuticals in a research note on Tuesday, February 13th. Finally, Zacks Investment Research raised shares of Vanda Pharmaceuticals from a “sell” rating to a “buy” rating and set a $17.00 price objective on the stock in a research note on Friday, April 20th.
Shares of NASDAQ VNDA traded down $0.15 during midday trading on Friday, hitting $14.45. 22,723 shares of the company traded hands, compared to its average volume of 697,160. Vanda Pharmaceuticals has a 12-month low of $11.90 and a 12-month high of $20.40. The stock has a market capitalization of $754.05, a P/E ratio of -41.71 and a beta of 1.12.
Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.08. Vanda Pharmaceuticals had a negative net margin of 9.43% and a negative return on equity of 11.94%. The company had revenue of $44.28 million for the quarter, compared to analysts’ expectations of $44.00 million. During the same quarter in the previous year, the company earned $0.08 earnings per share. Vanda Pharmaceuticals’s quarterly revenue was up 15.8% on a year-over-year basis. equities analysts anticipate that Vanda Pharmaceuticals will post -0.09 EPS for the current year.
In other news, CFO James Patrick Kelly sold 8,532 shares of the company’s stock in a transaction that occurred on Thursday, March 1st. The shares were sold at an average price of $18.72, for a total value of $159,719.04. Following the transaction, the chief financial officer now owns 208,066 shares in the company, valued at $3,894,995.52. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Mihael Hristos Polymeropoulos sold 60,966 shares of the company’s stock in a transaction that occurred on Thursday, March 1st. The stock was sold at an average price of $18.72, for a total transaction of $1,141,283.52. Following the completion of the transaction, the insider now owns 1,243,838 shares in the company, valued at approximately $23,284,647.36. The disclosure for this sale can be found here. Insiders have sold 78,023 shares of company stock worth $1,460,591 in the last three months. 7.60% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Bank of New York Mellon Corp lifted its stake in shares of Vanda Pharmaceuticals by 1.7% in the third quarter. Bank of New York Mellon Corp now owns 199,578 shares of the biopharmaceutical company’s stock worth $3,573,000 after buying an additional 3,305 shares in the last quarter. Teachers Advisors LLC lifted its stake in shares of Vanda Pharmaceuticals by 0.8% in the fourth quarter. Teachers Advisors LLC now owns 702,028 shares of the biopharmaceutical company’s stock worth $10,671,000 after buying an additional 5,690 shares in the last quarter. Sei Investments Co. lifted its stake in shares of Vanda Pharmaceuticals by 3.5% in the fourth quarter. Sei Investments Co. now owns 277,088 shares of the biopharmaceutical company’s stock worth $4,212,000 after buying an additional 9,417 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its stake in shares of Vanda Pharmaceuticals by 2.0% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 482,012 shares of the biopharmaceutical company’s stock worth $7,327,000 after buying an additional 9,496 shares in the last quarter. Finally, Strs Ohio lifted its stake in shares of Vanda Pharmaceuticals by 27.4% in the fourth quarter. Strs Ohio now owns 56,200 shares of the biopharmaceutical company’s stock worth $854,000 after buying an additional 12,100 shares in the last quarter. Hedge funds and other institutional investors own 81.10% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Vanda Pharmaceuticals Inc. (VNDA) Receives $20.40 Average Target Price from Brokerages” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/25/vanda-pharmaceuticals-inc-vnda-receives-20-40-average-target-price-from-brokerages.html.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.